(0.02%) 5 188.98 points
(0.48%) 39 070 points
(-0.19%) 16 301 points
(1.02%) $79.18
(-1.18%) $2.18
(-0.32%) $2 316.80
(0.07%) $27.56
(-0.11%) $987.35
(0.13%) $0.931
(0.08%) $10.91
(0.11%) $0.800
(0.19%) $91.62
Live Chart Being Loaded With Signals
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally...
Stats | |
---|---|
本日の出来高 | 1.18M |
平均出来高 | 916 661 |
時価総額 | 71.49B |
EPS | INR0 ( 2024-02-04 ) |
次の収益日 | ( INR0 ) 2024-05-19 |
Last Dividend | INR0 ( N/A ) |
Next Dividend | INR0 ( N/A ) |
P/E | -19.44 |
ATR14 | INR0.318 (0.14%) |
ボリューム 相関
Sun Pharma Advanced 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Sun Pharma Advanced 相関 - 通貨/商品
Sun Pharma Advanced 財務諸表
Annual | 2022 |
収益: | INR2.31B |
総利益: | INR592.00M (25.65 %) |
EPS: | INR-7.82 |
FY | 2022 |
収益: | INR2.31B |
総利益: | INR592.00M (25.65 %) |
EPS: | INR-7.82 |
FY | 2022 |
収益: | INR1.37B |
総利益: | INR105.52M (7.69 %) |
EPS: | INR-8.24 |
FY | 2021 |
収益: | INR2.53B |
総利益: | INR465.55M (18.40 %) |
EPS: | INR-5.77 |
Financial Reports:
No articles found.
Sun Pharma Advanced
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。